Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels
โ Scribed by Akiko Fujiwara; Kohsaku Sakaguchi; Shinichi Fujioka; Yoshiaki Iwasaki; Tomonori Senoh; Mamoru Nishimura; Masako Terao; Yasushi Shiratori
- Publisher
- Springer Japan
- Year
- 2008
- Tongue
- English
- Weight
- 181 KB
- Volume
- 43
- Category
- Article
- ISSN
- 0944-1174
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Current guidelines for management of chronic hepatitis B recommend treatment for patients presenting with elevated hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) >2 x upper limit of normal (ULN) or histological evidence of liver disease. Retrospective analyses have demonstrated that
The relationship between plasma hepatitis C virus (HCV) RNA levels, antibody positivity, and hepatocellular damage were studied i n 41 patients with non-A, non-B chronic liver disease. The patients were placed into t w o groups according to the plasma levels of HCV-RNA: plasma HCV-RNA level was esti
Many studies have demonstrated in animal experiments that persistent inflammation may accelerate the development of carcinoma. In this article, the question of whether the persistent elevation of serum alanine aminotransferase (ALT) levels (which represents the inflammatory necrosis of hepatocytes)